Taking phosphate binders may lower the risk of osteoporotic fractures in patients initiating dialysis. Oral phosphate binders may decrease the risk for osteoporotic fracture in patients starting ...

Nicotinamide and Lanthanum Carbonate and Changes in Serum Phosphate and Fibroblast Growth Factor-23 in Patients With CKD: The COMBINE Trial Inclusion criteria for this randomized, double-blind, ...

In a study, hemoglobin values did not differ meaningfully among daprodustat users, whether or not they also took one or more phosphate binders. Phosphate binders do not appear to substantially affect ...

Please provide your email address to receive an email when new articles are posted on . The Kidney Patient Act would delay placement of oral phosphate binders into ...

The non–calcium phosphate binder lanthanum carbonate (Fosrenol) had absolutely no effect on any intermediate marker of cardiovascular (CV) risk or bone and mineral metabolism in patients with ...

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially ...

Please provide your email address to receive an email when new articles are posted on . Of survey respondents, 47% said large number and large size of pills were among top phosphate binder adherence ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The type of ...

Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine. Tenapanor may reduce the number of phosphate binder pills patients on hemodialysis (HD) take daily to ...

LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...

The FDA approved the first-in-class phosphate absorption inhibitor tenapanor (Xphozah) to reduce serum phosphorus in chronic kidney disease (CKD) patients on dialysis, developer Ardelyx announced on ...